Prothena Corporation plc

Prothena Corporation plc is a biotechnology company whose core business model involves animal testing as an integral part of its drug development process. The company’s pipeline of investigational therapies for neurodegenerative diseases, including its lead programs for Alzheimer’s and Parkinson’s, relies on preclinical research conducted in animal models to assess safety and efficacy before human trials. This extensive use of animals in research is a standard but material component of its operations.

While specific financials for animal testing are not segregated in public filings, the company’s research and development expenses—which encompass these preclinical activities—totaled $338.5 million in 2023. Prothena’s business is fundamentally structured around the discovery and clinical testing of monoclonal antibodies, a process that inherently requires animal experimentation at multiple stages. The company has not published a policy or commitment to replace animal testing with alternative methods in its research pipeline.